Tonix Pharmaceuticals FY Conference Summary Company Overview - **Company Name**: Tonix Pharmaceuticals (NasdaqCM: TNXP) - **Focus**: Fully integrated pharmaceutical company with a focus on the launch of Tonmya, a treatment for fibromyalgia, and other therapeutic areas including migraine treatments [2][3] Key Products and Developments - **Tonmya**: - A sublingual cyclobenzaprine tablet approved for fibromyalgia treatment, launched on November 17, 2025 [4][6] - Targets disturbed sleep quality in fibromyalgia, addressing a high unmet need in a market with approximately 10 million adults affected in the U.S. [4][11] - Reported $1.4 million in net sales since launch [6] - Unique mechanism and first-in-class designation, with a focus on the 5% of prescribers who account for 70% of prescriptions [6][18] - **Migraine Treatments**: - Acquired two migraine products, Tosymra (sumatriptan nasal spray) and Zembrace (sumatriptan injection), but are gradually decreasing promotion of these products [19] Market Dynamics - **Fibromyalgia Market**: - High dissatisfaction with existing treatments, with only 3 million out of 10 million diagnosed and treated [12][13] - Potential for increased diagnosis among long COVID patients, with estimates suggesting 20-30 million may be affected [12] - Tonmya's pricing set at $1,860 per month for long-term use [18] - **Challenges and Opportunities**: - Need for education among prescribers about fibromyalgia and Tonmya [17][18] - Existing drugs for fibromyalgia are often misprescribed, with a significant reliance on opioids, which are not indicated for this condition [15][16] Clinical Pipeline - **Upcoming Studies**: - Lyme prophylactic program with promising phase one data, targeting a long-acting monoclonal antibody [27][28] - Studies for major depressive disorder and acute stress disorder funded by the U.S. Department of Defense [30] - Phase 2 study for kidney transplant treatment [31][32] Financial Position - **Financial Health**: - Ended the previous year with $208 million in cash and no debt, indicating a strong balance sheet [3] Conclusion - Tonix Pharmaceuticals is positioned for growth with a strong focus on addressing unmet needs in fibromyalgia and expanding its clinical pipeline. The company aims to leverage its unique product offerings and robust marketing strategies to capture a significant share of the market while navigating challenges in prescriber education and competition [33]

Core Insights - TNX-102 SL is a sublingual formulation of cyclobenzaprine aimed at treating fibromyalgia, with an FDA PDUFA goal date of August 15, 2025, potentially becoming the first new non-opioid analgesic for fibromyalgia in over 15 years [1][7] - The drug has shown statistically significant improvement in reducing fibromyalgia pain in two Phase 3 studies, demonstrating durable activity over 14 weeks [2][3] - TNX-102 SL targets sleep disturbances associated with fibromyalgia and has a favorable tolerability profile, acting as a potent antagonist at four post-synaptic receptors [3][6] Company Overview - Tonix Pharmaceuticals is a biotechnology company focused on developing therapies for pain management and CNS disorders, with TNX-102 SL as a priority product candidate for fibromyalgia [7] - The company has submitted a New Drug Application (NDA) for TNX-102 SL based on positive Phase 3 study results and has received Fast Track designation from the FDA [7] - Tonix also has a diverse development portfolio, including treatments for acute stress reactions, organ transplant rejection, and infectious diseases [7] Industry Context - Fibromyalgia affects over 10 million adults in the U.S., primarily women, and is characterized by chronic pain, non-restorative sleep, and cognitive dysfunction [4] - Current treatment options are often unsatisfactory, leading many patients to rely on chronic opioids, which carry risks of addiction and overdose [2][4] - TNX-102 SL's unique formulation aims to provide a new therapeutic option that addresses both pain and sleep disturbances without the risks associated with opioids [2][6]